Vitrolife AB (publ) VITR.ST
Nasdaq Stockholm · Healthcare · Medical Devices
120.10 SEK
−0.2%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Vitrolife
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 3,234 | 3,512 | 3,609 | 3,440 |
| EBITDA | 977 | −3,193 | 1,210 | −4,390 |
| Net income | 394 | −3,851 | 513 | −5,012 |
| Balance sheet | ||||
| Equity | 16,736 | 12,722 | 13,639 | 7,894 |
| Total debt | 2,225 | 2,089 | 2,089 | 1,605 |
| Cash | 578 | 861 | 1,135 | 809 |
| Net debt | 1,647 | 1,228 | 954 | 796 |
| Ratios and per share | ||||
| EBITDA margin | 30.2% | −90.9% | 33.5% | −127.6% |
| Profit margin | 12.2% | −109.7% | 14.2% | −145.7% |
| Return on equity | 2.4% | −30.3% | 3.8% | −63.5% |
| Earnings/share (SEK) | 2.91 | −28.43 | 3.79 | −37.00 |
| Book value/share (SEK) | 123.56 | 93.93 | 100.70 | 58.28 |
| Shares outstanding (M) | 135 | 135 | 135 | 135 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | – |
| P/B | 2.1 |
| EV / EBITDA | – |
| Net debt / EBITDA | – |
| Return on equity | −63.5% |
| Profit margin | −145.7% |
| Beta 1Y | 0.61 |
| Revenue growth 1Y | −4.7% |
| Revenue CAGR 3Y | +2.1% |
| ROE avg. 3Y | −30.0% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 1.10 |
| 2025 | 1.10 |
| 2024 | 1.00 |
| 2023 | 0.85 |
| 2022 | 0.80 |
Not investment advice. Figures may contain errors from the data source.